Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort study.
Adolescent
Adult
Aged
Antipsychotic Agents
/ therapeutic use
Cardiovascular Diseases
/ complications
Ethnicity
Female
Glycated Hemoglobin
/ analysis
Humans
Life Style
Male
Middle Aged
Obesity
/ complications
Prediabetic State
/ complications
Prospective Studies
Psychotic Disorders
/ complications
Regression Analysis
Risk Factors
Sex Factors
United Kingdom
Young Adult
First episode psychosis
cardiometabolic risk
ethnicity
glucose dysregulation
weight
Journal
The British journal of psychiatry : the journal of mental science
ISSN: 1472-1465
Titre abrégé: Br J Psychiatry
Pays: England
ID NLM: 0342367
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
pubmed:
28
7
2019
medline:
4
8
2020
entrez:
27
7
2019
Statut:
ppublish
Résumé
The first episode of psychosis is a critical period in the emergence of cardiometabolic risk. We set out to explore the influence of individual and lifestyle factors on cardiometabolic outcomes in early psychosis. This was a prospective cohort study of 293 UK adults presenting with first-episode psychosis investigating the influence of sociodemographics, lifestyle (physical activity, sedentary behaviour, nutrition, smoking, alcohol, substance use) and medication on cardiometabolic outcomes over the following 12 months. Rates of obesity and glucose dysregulation rose from 17.8% and 12%, respectively, at baseline to 23.7% and 23.7% at 1 year. Little change was seen over time in the 76.8% tobacco smoking rate or the quarter who were sedentary for over 10 h daily. We found no association between lifestyle at baseline or type of antipsychotic medication prescribed with either baseline or 1-year cardiometabolic outcomes. Median haemoglobin A1c (HbA1c) rose by 3.3 mmol/mol in participants from Black and minority ethnic (BME) groups, with little change observed in their White counterparts. At 12 months, one-third of those with BME heritage exceeded the threshold for prediabetes (HbA1c >39 mmol/mol). Unhealthy lifestyle choices are prevalent in early psychosis and cardiometabolic risk worsens over the next year, creating an important window for prevention. We found no evidence, however, that preventative strategies should be preferentially directed based on lifestyle habits. Further work is needed to determine whether clinical strategies should allow for differential patterns of emergence of cardiometabolic risk in people of different ethnicities.
Sections du résumé
BACKGROUND
The first episode of psychosis is a critical period in the emergence of cardiometabolic risk.
AIMS
We set out to explore the influence of individual and lifestyle factors on cardiometabolic outcomes in early psychosis.
METHOD
This was a prospective cohort study of 293 UK adults presenting with first-episode psychosis investigating the influence of sociodemographics, lifestyle (physical activity, sedentary behaviour, nutrition, smoking, alcohol, substance use) and medication on cardiometabolic outcomes over the following 12 months.
RESULTS
Rates of obesity and glucose dysregulation rose from 17.8% and 12%, respectively, at baseline to 23.7% and 23.7% at 1 year. Little change was seen over time in the 76.8% tobacco smoking rate or the quarter who were sedentary for over 10 h daily. We found no association between lifestyle at baseline or type of antipsychotic medication prescribed with either baseline or 1-year cardiometabolic outcomes. Median haemoglobin A1c (HbA1c) rose by 3.3 mmol/mol in participants from Black and minority ethnic (BME) groups, with little change observed in their White counterparts. At 12 months, one-third of those with BME heritage exceeded the threshold for prediabetes (HbA1c >39 mmol/mol).
CONCLUSIONS
Unhealthy lifestyle choices are prevalent in early psychosis and cardiometabolic risk worsens over the next year, creating an important window for prevention. We found no evidence, however, that preventative strategies should be preferentially directed based on lifestyle habits. Further work is needed to determine whether clinical strategies should allow for differential patterns of emergence of cardiometabolic risk in people of different ethnicities.
Identifiants
pubmed: 31347480
pii: S0007125019001594
doi: 10.1192/bjp.2019.159
pmc: PMC7557635
doi:
Substances chimiques
Antipsychotic Agents
0
Glycated Hemoglobin A
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
712-719Subventions
Organisme : Medical Research Council
ID : MR/N027078/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L022176/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U120097115
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0700995
Pays : United Kingdom
Organisme : Department of Health
ID : ICA-CL-2017-03-001
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N026063/1
Pays : United Kingdom
Références
Lancet Psychiatry. 2017 Jul;4(7):540-546
pubmed: 28624180
Br J Psychiatry. 2012 Dec;201(6):481-5
pubmed: 22955007
Comput Stat Data Anal. 2010 Oct 1;54(10):2267-2275
pubmed: 24748700
Am J Epidemiol. 2009 May 1;169(9):1133-9
pubmed: 19318618
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
Trials. 2016 Dec 12;17(1):594
pubmed: 27955680
Lancet Psychiatry. 2017 May;4(5):389-399
pubmed: 28330589
Addict Behav. 1978;3(3-4):235-41
pubmed: 735910
Obes Rev. 2017 Jul;18(7):715-723
pubmed: 28489290
Diabet Med. 2006 May;23(5):469-80
pubmed: 16681555
Schizophr Bull. 2010 Jan;36(1):71-93
pubmed: 19955390
Psychosomatics. 1995 May-Jun;36(3):267-75
pubmed: 7638314
Addiction. 1993 Jun;88(6):791-804
pubmed: 8329970
Schizophr Res. 2016 Mar;171(1-3):103-9
pubmed: 26805414
Schizophr Res. 1990 Jul-Aug;3(4):247-51
pubmed: 2278986
Psychol Med. 2015;45(12):2619-29
pubmed: 25961431
Am J Psychiatry. 2004 Feb;161(2):361-3
pubmed: 14754788
JAMA Psychiatry. 2017 Mar 1;74(3):261-269
pubmed: 28097367
Early Interv Psychiatry. 2016 Jun;10(3):193-202
pubmed: 25962699
Br J Psychiatry. 1978 Nov;133:429-35
pubmed: 728692
JAMA Psychiatry. 2015 Dec;72(12):1172-81
pubmed: 26509694
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Schizophr Bull. 2014 Jul;40(4):796-803
pubmed: 23943410
Psychopathology. 2006;39(4):175-8
pubmed: 16636640
Lancet Psychiatry. 2019 May;6(5):379-390
pubmed: 30975539
Fam Pract. 1994 Dec;11(4):375-81
pubmed: 7895964
Diabet Med. 2017 Jul;34(7):916-924
pubmed: 27973692
Br J Psychiatry. 1996 Jul;169(1):58-63
pubmed: 8818369
BMJ Open. 2014 Feb 06;4(2):e004138
pubmed: 24503301
Diabetes Care. 2011 Jul;34(7):1492-6
pubmed: 21602429
Arch Intern Med. 1992 Jun;152(6):1257-62
pubmed: 1599355
Schizophr Res. 2015 Oct;168(1-2):381-7
pubmed: 26278336
Schizophr Res. 2015 Oct;168(1-2):461-4
pubmed: 26189077
Int J Neuropsychopharmacol. 2013 Jun;16(5):987-95
pubmed: 23253821
Schizophr Res. 2006 Feb 28;82(2-3):225-31
pubmed: 16360305
Psychol Med. 2016 Nov;46(15):3231-3240
pubmed: 27605254
Schizophr Res. 2016 Feb;170(2-3):311-7
pubmed: 26718334
Br J Psychiatry. 2009 Dec;195(6):488-91
pubmed: 19949195
Early Interv Psychiatry. 2016 Jun;10(3):267-76
pubmed: 25721464